Catalysts · INSM · CIK 1104506 · page 2 of 2

INSM catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on INSM PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
June 10, 2025—INSMTopline readoutpulmonary arterial hypertensionPositivesec_424b
Jun 2025Month disclosedINS1201INSMTopline readoutPAH CompletedPositiveSEC 8-K Exhibit 99.1
May 8, 2025—INSMEarnings—CompletedSEC 8-K Exhibit 99.1
mid-2025Half-year disclosedINS1201INSMTopline readoutPAH Completed in December 2024ScheduledSEC 8-K Exhibit 99.1
February 18, 2025—INSMEarnings—CompletedSEC 8-K Exhibit 99.1
February 6, 2025BRINSUPRI® (brensocatib)INSMNDA/BLA acceptedbronchiectasisCompletedSEC Form 8-K
Q1 2025Quarter disclosedBRINSUPRI® (brensocatib)INSMPDUFA date—ScheduledSEC 8-K Exhibit 99.1
Dec 2024Month disclosedBRINSUPRI® (brensocatib)INSMTrial start—CompletedSEC Form 10-Q
Dec 2024Month disclosedBRINSUPRI® (brensocatib)INSMNDA/BLA submissionbronchiectasis with the UCompletedSEC 8-K Exhibit 99.1
May 2024Month disclosed—INSMTopline readout—PositiveSEC Form 10-Q
Mar 2024Month disclosedXHANCEINSMFDA approval—ApprovedSEC 8-K Exhibit 99.1
Sep 2023Month disclosedazithromycinINSMTopline readout—PositiveSEC 8-K Exhibit 99.1
October 19, 2020Arikayce Kit (amikacin sulfate)INSMLabel expansion—ApprovedopenFDA Drugs@FDA
September 28, 2018Arikayce Kit (amikacin sulfate)INSMFDA approval—ApprovedopenFDA Drugs@FDA
Every catalyst is quoted from INSM’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.